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Abstract 
 
Although a protocol aims to guide treatment management and optimize overall outcomes, the benefits and harms for 
each  individual  vary  due  to  heterogeneity.  Some  protocols  integrate  clinical  and  genetic  variation  to  provide 
treatment recommendation; it is not clear whether such integration is sufficient. If not, treatment outcomes may be 
sub-optimal for certain patient sub-populations.  Unfortunately, running a clinical trial to examine such outcome 
responses  is  cost  prohibitive  and  requires  a  significant  amount  of  time  to  conduct  the  study.    We  propose  a 
simulation approach to discover this knowledge from electronic medical records; a rapid method to reach this goal. 
We use the well-known drug warfarin as an example to examine whether patient characteristics, including race and 
the genes CYP2C9 and VKORC1, have been fully integrated into dosing protocols. The two genes mentioned above 
have been shown to be important in patient response to warfarin. 
 
Introduction 
 
A warfarin protocol aims to minimize the risks of anticoagulant treatment (i.e. stroke if under-dosed and hemorrhage 
if over-dosed) as well as improve overall costs by quickly identifying a therapeutic that will maintain stable and safe 
warfarin treatment.  
  
In general, the protocol guides warfarin treatment at two steps: initial dose for the first few days and maintenance 
therapy for the rest of treatment period. The first step aims to achieve stable treatment as quickly as possible; fixed 
dose and dosing algorithms based on clinical and genetic factors are often used at this step. The second step aims to 
continue the stable warfarin treatment by adjusting doses based on drug response: International Normalized Ratio 
(INR).  
 
Many patient characteristics (clinical and genetic factors such as CYP2C9) are associated with warfarin outcomes. A 
protocol fully integrated with important clinical and genetic factors to guide treatment makes warfarin management 
easier. These characteristics are known predictors of outcomes and dose requirement, so an efficient protocol that 
can guide treatment should take these factors into consideration. On the other hand, protocols which do not integrate 
these characteristics can recommend incorrect doses or dose adjustment, and may, consequently, result in poor 
outcomes for patient sub-populations.  
  
Comparing treatment outcomes against patient characteristics in clinical trials provides a gold-standard solution but 
is cost prohibitive and requires many years to conduct the study. Instead of clinical trials, we used a simulation 
method to discover such knowledge using electronic medical records (EMR) and identify patient sub-populations 
that tend to have poor outcomes for a treatment protocol.  
 
Background 
 
Warfarin, the vitamin K antagonist, is the  most  widely used anticoagulant in the  world to prevent stroke. The 
therapeutic  management  of  warfarin  is  highly  individualized  because:  (1)  Several  clinical  and  genetic  factors 
strongly influence drug metabolism; (2) The nature of warfarin’s narrow therapeutic index can easily result in a 
patient’s over-dosing (increasing risk of hemorrhage) or under-dosing (increasing risk of stroke).  
 
The common approach to achieving and maintaining therapeutic dose is to adjust based on the INR, an adjusted 
measure of coagulation time. A normal person’s INR is about one, and this will increase with the initiation of 
warfarin treatment. In general, a high INR (>3) is associated with an increased risk of hemorrhage, and a low INR 
(<2) is associated with an increased risk of stroke. Thus, patients face the risk of stroke before warfarin treatment 
19and both sides of the risk (hemorrhage and stroke) after starting the treatment. The optimal balance, INR target 
range, is between 2 and 3, achieving which is the goal for dosing adjustment. 
  
The risk of hemorrhage and stroke is small but definite [5]. Time in therapeutic range (TTR) is a commonly used 
surrogate risk measurement, which is the proportion of time in the target INR range (between 2 and 3).    
 
Due to recent efforts in genetic studies, many genes have been found to be related to warfarin metabolism and drug 
responses. Among them, CYP2C9 and VKORC1 are most frequently included in modern protocols, e.g., [2, 1, 7].  
 
One of the most famous clinical trials for the pharmacogenetic protocol is the Coumagen trial [1]. This clinical trial 
compares two protocols, pharmacogenetic (prediction of therapeutic dose based on clinical and genetic factors) and 
standard (predict therapeutic dose by INR measurements) with patient follow-up for up to 3 months. Although the 
pharmacogenetic protocol predicts the stable therapeutic dose more accurately (p<0.001), the primary end point, 
percentage of out-of-range INRs did not significantly differ from the standard protocol.  
 
Methods 
 
This section discusses each element of the clinical trial simulation platform. The platform was used to generate 
outcome  data  for  pharmacogenetic  and  standard  warfarin  dosing  protocols  used  by  the  Coumagen  trial  [1]. 
Sensitivity analyses were conducted to identify patient characteristics not appropriately integrated in both protocols.  
 
Table 1. Simulated Data Inputs                  
Parameter  Value type 
AGE (yrs)  Numeric 
HEIGHT (m)  Numeric 
WEIGHT (kg)  Numeric 
BSA (m
2) 
(body surface area) 
Numeric 
GENDER (male=1,female=0)  Categorical 
RACE 
(Caucasian, African-American, Asian, Unknown)  
Categorical 
TARGET_INR  Numeric 
CYP2C9 (*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3)  Categorical 
VKORC1 (B/B, A/B, A/A)  Categorical 
DVT (deep vein thrombosis, yes =1, no = 0)  Categorical 
SMOKING (yes = 1, no = 0)  Categorical 
AMI (amiodarone use, yes = 1, no = 0)  Categorical 
 
Data source. Data were collected by the International Warfarin Pharmacogenetics Consortium [7] which comprises 
21 research teams from 9 countries. The data consists of 5700 patients on warfarin treatment with demographic 
characteristics, primary indication for warfarin treatment, stable therapeutic dose and the corresponding INR, target 
INR,  concomitant  medications,  and  genotype  variants  of  CYP2C9  and  VKORC1.  Table  1  shows  a  subset  of 
variables selected for this simulation project. Before this project, we conducted a thorough literature review. We 
decided the variable set based on the highest compatibility to most dosing protocols and algorithms. 
 
Initial dose for warfarin treatment. The initial doses of warfarin treatment administered for the first two days are 
either fixed (at 10 mg/day) or pharmacogenetic [1] (based on the following function).  
 
Initial pharmacogenetic dose = 2*[(1.64 + exp(3.984 + CYP2C9- VKORC1 + AGE*(-0.009) + GENDER + 
WEIGHT*(0.003)))/7] 
 
Maintenance therapy for warfarin treatment. Both Coumagen protocols, standard and pharmacogenetic, adjust 
doses based on INR measurements to maintain safe treatment. In general, if INR is too low (<2), protocols suggest 
an increase a dose amount based on how far away the INR is from the target INR, and vise versa for a high INR (>3). 
In this simulation project, each patient receives warfarin treatment for 10 days. 
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PK/PD modeling for INR response.  We adapted the PK/PD model from Hamberg et al. [4] to predict the INR 
response for an individual with a given warfarin dose. Briefly, the PK/PD model was estimated from a set of 150 
patients.  Warfarin is a racemic mixture of two enantiomers S-warfarin and R-warfarin of which S-warfarin is 3-5 
times more potent and was shown to be the dominant factor. The authors indicate that the influence of warfarin 
therapy on INR response of the R warfarin was not statistically significant. Therefore, the model only considered the 
PK/PD effects of S-warfarin.  We modeled the PK effects using a two-compartment model with first order input and 
first order elimination and the PD effects using a two-chain transit compartment model.  Due to limitations on the 
original model it was necessary to make assumptions about the covariance of the variables because the complete 
covariance matrix was not provided. Many parameters and functions in this manuscript are provided in log form, 
and from our empirical test, the log normal distribution meets our expectation for parameter variation. Thus, we 
used a random log normal distribution to estimate the variability of the clearance rate, the volume in the central 
compartment, and the volume in the peripheral compartment and restricted the range to be within physiological 
ranges. 
 
To model the accumulation of warfarin concentration over time (assuming daily doses), we used the principle of 
superposition.  Superpositioning does not require assumptions regarding a PK model or absorption kinetics, but 
instead assumes each dose of the drug acts independently and that the rate and extent of absorption and average 
systemic clearance are the same for each dosing interval and that linear PK apply [3].  We created a table of warfarin 
concentrations over time and summed across the rows at 24-hour time intervals to predict the amount of wafarin 
remaining in the system.  The results agree with previously published methods [3, 4]. 
 
Outcome metric. The time points where INR is measured depend on the protocols. INRs of a patient are further 
converted to time in therapeutic range (TTR), which is the proportion of time a patient’s INRs fall within the 
target range between 2 and 3.  
 
Clinical trial simulation. Figure 1 summarizes the clinical trial simulation platform. For the first two days, each 
simulated patient receives initial warfarin treatment, either a pharmacogenetic dose or a 10 mg fix dose. From days 3 
to 10, doses are adjusted according to protocol to reach the target INR range and maintain therapy. The PK/PD 
model predicts INRs, which are measured at times specified by the protocols. 
 
 
We ran a two armed simulation with 5700 patients per arm. The patient population in each arm was identical, and 
each was assigned to one of the two protocols.  We then repeated the simulation 100 times in order to capture the 
variance of INR outcomes. Each iteration’s INRs were further converted to TTR. 
  
Apply sensitivity analysis to identify patient characteristics. 1,140,000 simulations (5700 patients × 2 protocols × 
100 iterations) were conducted. For simplicity, we took the average TTR of the 100 iterations to represent each 
simulated patient’s TTR. Two sets of TTRs (one for each protocol) for 5700 simulated patients constitute the final 
data for the next analysis.  
Initial 
doses 
Simulated 
patients 
Measure 
INR 
Dosing 
adjustment 
Figure 1. The simulation process.  Each simulated patient 
receives warfarin for 10 days. Simulated patients receive 
initial doses for 2 days. Times to measure INR and adjust 
doses depend on protocols for days 3 to 10. 
Days 1-2  Days 3-10 
Figure  1.  The  simulation  process.    Each  simulated 
patient receives warfarin for 10 days: initial doses for 
2  days  and  dosing  adjustment  from  days  3  to  10. 
Time to measure INR depends on the protocols. 
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Sensitivity analysis (SA) [6] is a common way to identify how different values of a variable influence the variation 
of output. This project used standardized regression coefficients implemented in R for the SA.  
 
Three important variables: race, CYP2C9, and VKORC1, are chosen for the SA. In order to understand the influence 
of a certain value of a variable can take to TTR variation (for example, TTR variation due to presence of the 
characteristic: African American), we further convert each variable possibility into a binary dummy variable. For 
example, the four race groups, Caucasian, Asian, African American, and Unknown are represented by four dummy 
variable sets ([1,0,0], [0,1,0], [0,0,1], and [0,0,0], respectively) which will pull out the appropriate coefficients from 
our regression equations.  
 
Results 
 
 
 
   
Figure 2. Sensitivity scores of four race groups and three VKORC1 genotypes for pharmacogenetic and standard protocols. 
Unknown race group and VKORC1 genotype B/B are reference group so they are absent from the figure. Observed TTRs of four 
race groups, Caucasian, Asian, A_A, and Unknown, for Coum-Pharm and Coum-STD are [0.618, 0.63, 0.62, 0.622] and [0.641, 
0.72, 0.58, 0.658], respectively.  Observed TTRs of VKORC1 genotypes, AA, AB, and BB, for Coum-Pharm and Coum-STD are 
[0.635, 0.631, 0.622] and [0.736, 0.675, 0.658], respectively. 
 
 
The average TTRs of 5700 patients for the pharmacogenetic and standard protocols are 0.622 and 0.658 (SD 0.149 
and 0.164) respectively. Figure 2 shows  sensitivity scores for the  four race  groups  (Caucasian,  Asian,  African 
American, and Unknown) and three VKORC1 genotypes (A/B, A/A, and B/B). Unknown race and B/B (wild type 
of VKORC1) are the reference group. The Y axis shows standardized coefficients or sensitivity scores. The scores 
of most characteristics in pharmacogenetic protocol are close to 0 and TTRs are very consistent. This indicates the 
protocol successfully integrates these characteristics. This is because the protocol guides the initial treatment based 
on  these  characteristics  and  thus  captures  the  factor-dependent  variation  in  patients’  dosing  requirement. 
Consequently TTR variations are low.  It is interesting to note that although the initial doses depend on clinical and 
genetic factors, dose adjustment for days 3 to 10 is only based on INRs. As a result, we conclude that the initial dose 
predictions sufficiently capture and propagate the variation due to these characteristics. 
 
On the other hand, the standard protocol fails to integrate most of these characteristics. Compared to the reference 
group, Compared to Unknown race, Asian is positively associated with TTR, but African American is negatively 
associated with TTR. In addition, the observed TTR for African American and wild type (BB) VKORC1 are the 
lowest  among  their  respective  factor  values  (0.58  and  0.658,  respectively).  These  results  indicate  that  African 
Americans  and  persons  with  VKORC1  genotype  B/B  should  be  appropriated  more  attention  when  receiving 
warfarin treatment based on the standard protocol because they tend to have low TTR, and consequently, higher 
risks of hemorrhage and stroke.  
 
Figure  3  shows  sensitivity  scores  for  six  CYP2C9  genotypes  (*1/*1,  *1/*2,  *1/*3,  *2/*2,  *2/*3,  and  *3/*3 
corresponding to CYP11, CYP12, CYP13, CYP22, CYP23,  and  CYP33,  respectively)  for  both  protocols. 
Genotype *1/*1 (wild type) is the reference group. Neither the pharmacogenetic nor standard protocols sufficiently 
integrate variant CYP2C9 genotypes, especially CYP33, which is negatively associated with TTR (compared to 
      Coum-Pharm                     Coum-STD        Coum-Pharm                     Coum-STD 
Races                 VKORC1 
22CYP11)  and  shows  the  lowest  TTRs  (0.392  for  pharmacogenetic  and  0.484  for  standard  protocols). Thus,  the 
simulation framework determined that patients with CYP33 may be more at risk for an adverse event when they 
receive warfarin treatment based on either protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
We propose a simulation approach to examine which patient characteristics a protocol “captures” and integrates. 
Several  patient  characteristics  (see  Table  1)  influence  warfarin  outcomes.  When  a  protocol  captures  important 
characteristics  and  accurately  integrates  them,  patients  displaying  these  characteristics  will  receive  effective 
individualized treatment. Consequently, TTR variation between patients with these characteristics will be low.  
  
We note that a protocol integrating important characteristics does not guarantee the protocol to have a high overall 
TTR. More complex issues such as the number of integrated characteristics, the weights of these characteristics, and 
interaction among characteristics should be considered. Rather it indicates people with these characteristics can 
equally benefit from the protocol, showing similar TTR measurements.  
 
The simulation framework can identify patient sub-populations (when treated based on a certain protocol) that tend 
to have poor outcomes. Precautions can then be taken to reduce the chance of having a poor outcome in these sub-
populations. 
 
This proposed method merges three distinctive knowledge sources; dosing protocols, an INR model, and EMRs, and 
integrates them into the simulation framework for knowledge discovery. The three knowledge sources, which exist 
in  various  forms,  provide  different  aspects  of  information:    protocols,  which  exist  in  the  forms  of  tables  and 
algorithms, guide warfarin dosing; the INR model, which exists in the form of a complex two-compartment model, 
predicts  dynamic  INR  measurements;  finally,  PharmGKB,  EMR  data  provides  patient  characteristics  and  their 
interactions needed for the INR model and protocol predictions which generate TTR and facilitate the discovering 
process.  This  project  demonstrates  that  a  sophisticated  simulation  algorithm  can  discover  valuable  clinical 
knowledge from mixed types of data sources.  
 
Each element in the proposed approach is highly modularized. One can easily replace the PharmGKB data, INR 
model, or protocol for other research purposes. In addition, we can use this simulation platform to examine which 
characteristics a newly designed warfarin protocol is able to capture and compare advantages and disadvantages 
among other existing protocols.  
Figure 3. Sensitivity scores of six CYP2C9 genotypes for both 
protocols.  Both  phrmacogenetic  and  standard  protocols  does 
not well control variant types of CYP2C9, especially CYP33. 
Observed  TTRs  of  CYP2C9  genotypes,  CYP33,  CYP23, 
CYP22,  CYP13,  CYP12,  and  CYP11,  for  Coum-Pharm  and 
Coum-STD are [0.392, 0.527, 0.588, 0.612, 0.634, 0.622] and 
[0.484, 0.625, 0.599, 0.688, 0.681, 0.658] 
      Coum-Pharm                  Coum-STD 
CYP2C9 
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Future work will expand the current work to a large number of protocols and allow for protocol comparison. We 
also  plan  to  use  different  INR  models,  compare  them,  and  further  improve  the  simulation  platform.  More 
importantly, we will refine the platform to support comparative effectiveness research that allows comparison of not 
only TTR but also other outcome metrics, such as bleeding and thrombosis risks, and treatment costs. 
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